Project description
Host-directed interventions to cure hepatitis B infections
The objective of the EU-funded IP-cure-B project is to develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine. Researchers will also identify immune and viral biomarkers for patient stratification and treatment response monitoring. Integration of biological and clinical data will enable models for the best combination treatment and effectiveness of novel curative therapies with respect to disease spectrum and patient heterogeneity. The preclinical platform will be evaluated in humanised mice, combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses. Proof of concept will be obtained in a clinical trial of a combination of novel compounds stimulating innate immunity.
Field of science
- /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
- /natural sciences/biological sciences/genetics and heredity/mutation/virus mutation
- /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
Programme(s)
Call for proposal
H2020-SC1-2019-Two-Stage-RTD
See other projects for this call
Funding Scheme
RIA - Research and Innovation actionCoordinator
75654 Paris
France
Participants (13)
1011 Lausanne
17177 Stockholm
75724 Paris Cedex 15
43100 Parma
20122 Milano
79106 Freiburg
10561 Athina
08035 Barcelona
94404 Foster City Ca
19801 Wilmington
1040 Bruxelles
75013 Paris
69002 Lyon
